Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus, a leader in simulation and modeling software for pharmaceutical development, announced that CEO Shawn O'Connor will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10, 2020, at 3:30 p.m. ET. His presentation will be available via a live webcast, and a slide presentation can be accessed on the company's Investors page afterwards. Simulations Plus provides advanced modeling solutions utilized by major pharmaceutical and regulatory agencies worldwide.
Simulations Plus (Nasdaq: SLP), through its subsidiary Lixoft, has announced the release of MonolixSuite version 2020R1, enhancing population PKPD modeling solutions. Key improvements include an upgraded Simulx module with a user-friendly GUI, new dataset filters, a tumor growth inhibition library, and advanced capabilities for non-compartmental analysis (NCA). These updates aim to streamline modeling and simulation processes in drug development. Lixoft emphasizes user experience and advanced statistical methods that align with industry demands.
DILIsym Services, a Simulations Plus company (Nasdaq: SLP), announced that its DILIsym® software was referenced in the FDA's review of the New Drug Application for Pexidartinib (Turalio®), marking a milestone as the first systemic therapy for tenosynovial giant cell tumor. The FDA noted DILIsym's utility in assessing hepatocellular injury and its impact on safety predictions in drug development. The software aids in identifying drug-induced liver injury risks, potentially influencing regulatory decisions and benefiting patient safety.
Simulations Plus, Inc. (Nasdaq: SLP) has announced the launch of version 9.8 of its leading modeling and simulation platform, GastroPlus®. This update features key enhancements such as the industry's first mechanistic model for intra-articular delivery and a revamped bioequivalence trial simulation engine, aligning with new FDA guidelines. The company emphasizes its commitment to improving drug development efficiency, as highlighted by collaborations with various industry partners. These improvements are aimed at enhancing clinical pharmacology capabilities and drug-drug interaction simulations.
Simulations Plus, Inc. (Nasdaq: SLP) has received a new FDA cooperative agreement to develop in vitro/in silico models for oral drug administration. This partnership with St. Louis College of Pharmacy aims to enhance pharmaceutical research for innovative and generic products. Using the Dynamic In Vitro Dissolution and Absorption Model, the project will improve the characterization of oral formulations. FDA staff will collaborate on the research, continuing a series of funded collaborations that bolster the company's reputation in modeling and simulation solutions for the pharmaceutical industry.
Simulations Plus (Nasdaq: SLP) has declared a quarterly cash dividend of $0.06 per share, set for distribution on November 2, 2020. Shareholders of record by October 26, 2020 will receive this dividend, continuing the board's commitment to regular quarterly dividends. The board will evaluate future dividends based on the company's earnings, financial condition, and capital requirements. Simulations Plus specializes in modeling and simulation solutions for the pharmaceutical and biotechnology sectors.
Simulations Plus (NASDAQ: SLP) has accelerated the second phase of its collaboration with a major pharmaceutical firm to enhance its high-throughput pharmacokinetic (HTPK) simulation capabilities within ADMET Predictor®. This collaboration follows positive feedback from the first phase and aims to improve lead selection for small molecule programs. The company emphasizes the benefits of tailored functionalities for its partner, which will enhance research timelines and medication development for patients.